CTI BioPharma (CTIC) Misses Q4 EPS by 9c, Offers Guidance
Get Alerts CTIC Hot Sheet
Price: $9.09 --0%
Revenue Growth %: -100.0%
Financial Fact:
Foreign exchange gain (loss): -69K
Today's EPS Names:
SHIM, KOD, HEWA, More
Revenue Growth %: -100.0%
Financial Fact:
Foreign exchange gain (loss): -69K
Today's EPS Names:
SHIM, KOD, HEWA, More
Join SI Premium – FREE
CTI BioPharma (NASDAQ: CTIC) reported Q4 EPS of ($0.27), $0.09 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $17.8 million, may not compare to the consensus estimate of $2.48 million.
CTI BioPharma sees FY2015 revenue of $50-55 million, versus the consensus of $50.17 million. CTI BioPharma expects that non-GAAP operating loss for 2015 will be approximately $75 million to $85 million, which excludes non-cash share-based compensation expense.
For earnings history and earnings-related data on CTI BioPharma (CTIC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: RH, Estee Lauder rise; Tesla falls
- Planet Labs (PL) Reports In-Line Q4 EPS, provides guidance
- Surf Air Mobility Inc. (SRFM) Reports revenue, provides guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!